MY-943 - Moligand™, 10 mM in DMSO

Cat. No.: M1497588

GRADE & PURITY Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

개요

MY-943 is a potent tubulin polymerization and LSD1 inhibitor with anticancer activity. MY-943 induces G2/M phase arrest and apoptosis , and inhibits cell migration. MY-943 can be used for gastric cancer research.

Specifications

사양 및 순도

Moligand™, 10 mM in DMSO

보관 조건

Store at -80°C

배송

Dry ice packs + Cold packs

이 제품은 콜드 체인 배송이 필요합니다.지상 및 기타 경제 서비스는 사용할 수 없습니다.

등급

Moligand™

작업 유형

ACTIVATOR

Application Protocols

Item-specific validated applications are not provided for MY-943.

General protocols for small-molecule test articles (research use only)

• Stock preparation
  • Weigh under low humidity if hygroscopicity is suspected. Dissolve in anhydrous DMSO to 10 mM. Vortex and, if needed, sonicate briefly. Record exact concentration by weight-in/volume-out; for high precision, quantify by UV or qNMR.
• Plate handling
  • Dispense into polypropylene plates or tubes to minimize adsorption. Seal plates (heat seal or cap mats) and store at −80 °C when possible. Limit freeze–thaw cycles by aliquoting.
• Assay setup
  • Maintain constant vehicle (e.g., 0.5% DMSO) across all wells. Include vehicle and positive/negative controls. Mix thoroughly after dosing; check for precipitation.
• Data integrity
  • Verify compound presence by LC–MS spot-checks on representative wells. Track well identity and barcodes to prevent sample swaps.

Always refer to your internal SOPs and the SDS/CoA for item-specific handling.

Biological Roles

Item-specific data

• No target, pathway, or mode-of-action information is provided for MY-943.

General guidance

• For undetermined small molecules, biological roles are established empirically through a tiered approach:
  • Primary screens: detect any activity in target-based or phenotypic assays.
  • Secondary assays: confirm potency and efficacy under varied conditions, including counter-screens against assay interference.
  • Mechanism-of-action studies: use chemoproteomics, CETSA/thermal shift, CRISPR modifier screens, or profiling across annotated panels to infer targets.
• If structure becomes available, in silico predictions (polypharmacology, ADMET alerts, PAINS filters) can inform prioritization. Any computational hypothesis should be validated experimentally.

Note

• Until specific data are provided for MY-943, avoid assigning biological function or target specificity. Treat MY-943 as a research test article only.

Buffer Applications

Not typically applicable as MY-943 is a small-molecule test article, not a buffering reagent.

Practical guidance for delivering MY-943 into buffers (general)

• Prepare a concentrated DMSO stock (e.g., 10 mM) and dilute into assay buffer to a final solvent level tolerated by the system (commonly ≤0.5–1% v/v DMSO).
• To mitigate precipitation upon dilution:
  • Add compound stock last, with rapid mixing.
  • Match temperatures of stock and buffer; warming slightly (25–37 °C) can help.
  • Consider low levels of non-ionic surfactant (e.g., 0.01% Tween 20/80) if compatible.
• Common assay buffers (examples; literature/general):
  • Enzyme assays: HEPES or Tris (pH 7.0–8.0) with 0.01–0.05% detergent for aggregation control.
  • Binding assays: PBS or HBS-EP derivatives; maintain constant DMSO in running/binding buffers.
• Always verify compound remains in solution by post-dilution visual inspection and, when critical, by LC–MS or UV monitoring.

Green Alternatives

Applicability

• As MY-943 is a screening compound without specified synthesis or solvent use, green considerations center on solvent choices for handling and assays rather than on a specific reaction.

Greener handling options (general)

• Reduce DMSO where feasible by:
  • Using concentrated DMSO stocks with low final assay percentage (≤0.5–1% v/v) and validating assay tolerance.
  • Exploring ethanol or glycerol/PEG-400 cosolvents when compatible with biological systems and analytics.
• Minimize waste by preparing micro-aliquots to avoid freeze–thaw cycles and disposal of expired bulk solutions.

Comparison of common delivery solvents (general considerations)

• DMSO: Excellent solvency; not classed as highly hazardous but can enhance dermal absorption; high boiling point complicates recovery.
• Ethanol: Renewable feedstock; flammable; broadly accepted in green solvent guides.
• Water-buffer with small co-solvent: Greenest carrier when solubility allows; ensure compound remains in solution.

Operational strategies

• Use acoustically dispensed nanoliter volumes to reduce solvent consumption.
• Prefer sealed, low-dead-volume plates to limit evaporation and VOC emissions.

Pharmaceutical Uses

No pharmaceutical or excipient uses are specified for MY-943. This product is labeled for research use only.

General note

• Library compounds such as MY-943 may be evaluated in discovery research settings but are not manufactured to pharmacopeial standards and are not intended for human or veterinary use. Do not use in clinical or diagnostic applications.
• If future formulation studies are contemplated in preclinical research, obtain the full identity, impurity profile, salt form, and stability data and conduct suitability assessments according to internal nonclinical SOPs.

Physical Properties

Item-specific values

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Density, melting point, boiling point, refractive index, logP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General small-molecule screening compound considerations (literature/general)

• Many screening compounds are designed to be soluble in DMSO at 10–50 mM. If solubility is uncertain, begin with 10 mM in anhydrous DMSO and check clarity after vortex/sonication.
• If aqueous delivery is required, typical cosolvent percentages for assays: 0.1–1% v/v DMSO final (confirm assay tolerance). For poorly soluble chemotypes, consider co-solvent blends (DMSO:PEG-400:water or DMSO:EtOH:water).
• Ionizable compounds: solubility can be improved by adjusting pH (acidic compounds dissolve better at basic pH; basic compounds at acidic pH). Only apply after confirming ionization behavior from CoA or structure.

Practical tips

• Filter solutions (0.22 μm PTFE or PVDF) if particulate persists and if the compound is not adsorptive; avoid nylon for strongly hydrophobic or acidic compounds.
• Record exact solvent lot and water content for reproducibility; hygroscopic uptake can change effective concentration over time.

Quality and Grades

Item-specific grade

• Grade/Purity: Moligand™ (from Product Data).

What Moligand™ typically signifies (general description)

• Moligand-grade items are intended for research screening and ligand discovery workflows. While exact specifications are not provided here, such designations often indicate suitability for high-throughput screening, fragment-to-lead efforts, or ligandability studies. This may include batch traceability, library compatibility (e.g., DMSO-soluble), and availability of structural/analytical documentation upon request.

Documentation and verification

• For this specific item, detailed specifications (purity percentage, residual solvents, salt form, water/peroxide content, metal limits, and UV cutoffs) are Not specified for this item; refer to CoA/Spec Sheet.
• Request the CoA to verify: identity confirmation method (e.g., 1H NMR, LC–MS, HRMS), purity method and threshold (e.g., HPLC area %), and counterion/salt form.

Practical implications

• For screening: validate purity and identity before committing to hit triage. Run an orthogonal purity check under your method (e.g., UHPLC-UV at dual wavelengths and LC–MS). Confirm absence of interfering fluorescence/UV tails if using optical readouts.
• If stability is uncertain, perform an accelerated stability check of the working stock (e.g., 1 week at 4 °C and room temperature in DMSO) using LC–MS to assess degradation.

Reaction and Applications

Item-specific scope

• MY-943 is listed in a small-molecule/compound library context, suggesting use in screening, target engagement studies, and SAR exploration. No specific reactivity or functional groups are provided.

Discovery and screening uses (general)

• Biochemical/biophysical assays: evaluate as a test article in enzyme inhibition/activation, receptor binding (SPR/BLI), or thermal shift assays (DSF). Maintain consistent DMSO across wells and include vehicle controls.
• Phenotypic assays: apply in cell-based or organismal models to identify activity signatures. Track effective assay window and any cytotoxicity baseline.
• Orthogonal confirmation: Use LC–MS to verify compound presence in assay wells (post-run) to rule out adsorption/precipitation artifacts.

Hit development workflow (general practical tips)

• Authenticity: Cross-check with CoA; confirm by 1H NMR and LC–MS.
• Purity/aggregation: Assess with HPLC-UV and DLS/AUC if PAINS/aggregator risk is suspected.
• Solubility/stability: Measure kinetic solubility in assay buffer at intended concentration; monitor degradation by LC–MS over 24–72 h.
• SAR enablement: If structure is disclosed, design close analogs to probe substituent effects, polarity, and metabolic liabilities.

Assay interference mitigation

• Include redox, fluorescence, and detergent sensitivity controls. Apply counter-screens for promiscuous mechanisms (e.g., colloidal aggregation via detergent reversibility tests).

Reaction Conditions

Not applicable to this item as-supplied. MY-943 is provided as a small-molecule screening compound with no disclosed functional groups or intended synthetic transformations.

General guidance (if derivatization is later pursued; literature/general)

• Select conditions based on the revealed scaffold: aromatic halides favor Pd-catalyzed cross-couplings; heteroatom nucleophiles may require milder bases; sensitive motifs may necessitate photoredox or electrochemical conditions.
• Always confirm compatibility with any protecting groups and assess stability in the chosen solvent and temperature window before scale-up.

Safety and Handling

Item-specific hazard information

• Signal word: Not specified for this item; refer to SDS.
• H-statements: Not specified for this item; refer to SDS.
• GHS classification: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

General laboratory safety for unknown small molecules

• Handle in a chemical fume hood; avoid inhalation, ingestion, and skin/eye contact. Assume potential for irritation or sensitization until hazard data are confirmed.
• Personal protective equipment (PPE): lab coat, safety glasses or splash goggles, and suitable chemical-resistant gloves (e.g., nitrile). Change gloves regularly; double-glove for concentrated DMSO solutions due to enhanced dermal penetration.
• Incompatibilities: Without structural data, avoid strong oxidizers/reducers, strong acids/bases, and reactive metals. Keep away from ignition sources if dissolved in flammable solvents.
• First aid (overview; consult SDS for authoritative guidance):
  • Skin contact: Remove contaminated clothing, wash with soap and water. Seek medical attention if irritation persists.
  • Eye contact: Rinse with water for at least 15 minutes; obtain medical attention.
  • Inhalation: Move to fresh air; seek medical attention if symptoms occur.
  • Ingestion: Rinse mouth; do not induce vomiting; seek medical advice.
• Waste disposal: Collect solutions and solids as organic chemical waste; follow institutional and local regulations.
• Special risks: DMSO stock solutions increase dermal absorption of solutes; practice strict avoidance of skin contact. Avoid aerosol generation when plate pinning or acoustic dispensing.

Solvent Selection

Item-specific note

• No solubility or polarity data are provided for MY-943. The following are general, structure-agnostic strategies for small-molecule library members.

Primary stock solvent

• DMSO (anhydrous) is the default for discovery libraries. Start at 10 mM; increase to 50–100 mM only after confirming solubility and stability.

Co-solvent and transfer strategies

• If precipitation occurs upon aqueous dilution, consider:
  • Co-solvents: DMSO:PEG-400:water (5:5:90) or DMSO:EtOH:water (1:4:95) while keeping final DMSO ≤1% v/v in assays as tolerated.
  • Surfactants (only if compatible with assay): 0.01–0.05% Tween 80 or Pluronic F-68 to maintain dispersion.
  • pH conditioning: For acids, deliver into basic buffer; for bases, deliver into acidic buffer (only after confirming ionization state from structure/CoA).

Comparison of common delivery solvents (general)

• DMSO: high solvency, miscible with water; can affect cells/enzymes above 1–2% v/v.
• Ethanol: good for lipophiles; flammable; biological tolerance often ≤1% v/v.
• Acetonitrile: miscible, UV-transparent; may denature proteins at modest percentages.

Tips

• Warm to 25–37 °C and vortex/sonicate before judging insolubility.
• Filter through 0.22 μm PTFE if compatible. Avoid adsorption by testing recovery with a standard LC–MS assay.

Storage and Reconstitution

Item-specific storage information

• Storage conditions: Store at −80 °C (from Product Data).
• Shipped in: Dry ice packs + Cold packs (from Product Data).
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.

General best practices for small-molecule library compounds

• Upon receipt: Keep frozen (−80 °C). Allow the shipping container to equilibrate to room temperature before opening to minimize condensation. Quickly transfer vials/plates to −80 °C storage.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze–thaw. For solids, subdivide under dry air or nitrogen; for solutions, dispense into low-bind, airtight tubes or sealed plates.
• Reconstitution
  • Solvent: Use anhydrous DMSO unless otherwise specified. Typical starting concentration: 10 mM.
  • Procedure: Warm vial to room temperature in a desiccator, add pre-warmed solvent, vortex, and sonicate briefly if needed. Inspect for clarity; if insoluble, consider incremental solvent addition or compatible co-solvents.
• Stability
  • Working solutions in DMSO are generally stable at −20 to −80 °C; however, item-specific stability is Not specified for this item; refer to CoA/Spec Sheet.
  • Avoid light if chromophoric groups are suspected; store in amber vials or wrapped plates as a precaution.
• Handling
  • Minimize exposure to ambient humidity; recap promptly. Document preparation date, concentration, and number of freeze–thaw cycles for quality tracking.

Structure and Identity

This product is listed as a Moligand small-molecule library member (code: MY-943). No structure identifiers are provided in the product data.

Item-specific facts (from Product Data)

• SKU: M1497588
• Product name: MY-943
• Grade/Purity: Moligand™
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• CAS: Not specified for this item; refer to CoA/Spec Sheet.
• CID: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

• 2D/3D structure, functional groups, ring systems, and stereochemistry: Not specified for this item; refer to CoA/Spec Sheet or library annotation.

General guidance

• For cheminformatics tracking, request the CoA/Spec Sheet for structure identifiers and exact composition. If supplied under a coded library, structures may be disclosed under CDA/NDA or after hit validation.
• If using in screening plates, index MY-943 by SKU and well position; maintain link to any internal structure database to prevent decoding errors.

Synthetic Utility

Item-specific context

• No structural information is provided for MY-943; therefore, no specific synthetic transformations or functional group reactivity can be described for this item.

General remarks for library compounds

• If the structure is disclosed, synthetic utility can be considered in two directions:
  • Analog synthesis (SAR): define modifiable vectors and plan convergent routes to access matched pairs and small focused sets.
  • Derivatization for probes: incorporate handles (alkynes, azides, amines) for immobilization or reporter attachment while preserving activity.
• Practical considerations:
  • Confirm absolute/relative stereochemistry if chiral; use enantioselective or resolution strategies for single-enantiomer libraries.
  • Map late-stage diversification options (C–H functionalization, cross-coupling, SuFEx, photoredox) to accelerate analog generation once the core scaffold is validated.

Note

• For MY-943 specifically, consult the CoA/Spec Sheet for functional groups and any disclosed synthetic lineage before planning derivatization.

Target Specificity

No target, epitope, or specificity information is provided for MY-943.

Note

• For small molecules, target specificity is established experimentally via binding assays, selectivity panels, or chemoproteomic pull-downs. Until such data are supplied, treat MY-943 as a non-annotated research compound.

자주 묻는 질문

What is Moligand??

Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.